5-chloro-2-methyl-8-morpholino-6-(pyridin-3-yl)imidazo[1,2-a]pyrazine | 1252594-83-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡嗪类
• 英文名称: 5-chloro-2-methyl-8-morpholino-6-(pyridin-3-yl)imidazo[1,2-a]pyrazine
• 英文别名: 4-(5-Chloro-2-methyl-6-pyridin-3-ylimidazo[1,2-a]pyrazin-8-yl)morpholine
• CAS: 1252594-83-4
• 化学式: C₁₆H₁₆ClN₅O
• 分子量: 329.789
• InChiKey: CENUCRXUCXKMFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  55.6
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS
  申请人：Pastor Fernández Joaquin

  公开号：US20120083492A1

  公开（公告）日：2012-04-05

  There is provided compounds of formula (I), wherein R 1 , R 2 , R 3 , R 4 and R 5 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

  提供了式(I)的化合物，其中R1、R2、R3、R4和R5在描述中有给定的含义，以及它们的药用可接受的酯、酰胺、溶剂合物或盐，这些化合物在治疗需要或期望抑制蛋白质或脂质激酶（例如PI3-K和/或mTOR）的疾病方面非常有用，特别是在治疗癌症或增生性疾病方面。
• IMIDAZOPYRAZINES AS INHIBITORS OF PROTEIN KINASES
  申请人：Centro Nacional de Investigaciones Oncológicas (CNIO)

  公开号：EP2419429B1

  公开（公告）日：2014-03-26
• US8778935B2
  申请人：——

  公开号：US8778935B2

  公开（公告）日：2014-07-15
• [EN] IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS<br/>[FR] IMIDAZOPYRAZINES POUR UNE UTILISATION EN TANT QU'INHIBITEURS DE KINASE
  申请人：CT NAC DE INVESTIGACIONES ONCO

  公开号：WO2010119264A1

  公开（公告）日：2010-10-21

  There is provided compounds of formula (I), wherein R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.
• [EN] COMBINATIONS OF PI3K INHIBITORS WITH A SECOND ANTI -TUMOR AGENT<br/>[FR] COMBINAISONS D'INHIBITEURS DE PI3K AVEC UN SECOND AGENT ANTITUMORAL
  申请人：CT NAC INVESTIGACIONES ONCOLOGICAS CNIO

  公开号：WO2012052745A1

  公开（公告）日：2012-04-26

  There is provided combinations comprising (A) a compound of formula (I), wherein R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, together with (B) one or more therapeutics agents/treatments known to be useful in the treatment of diseases such as cancer or a proliferative disease, which combinations are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.